ArticleCureus2026
Pulmonary Tuberculosis Masking Lung Adenocarcinoma: A Diagnostic Pitfall Following Apparent Treatment Response.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary tuberculosis and lung cancer may present with overlapping clinical and radiological features, making diagnosis challenging. We report the case of a 42-year-old chronic smoker with bacteriologically confirmed pulmonary tuberculosis who showed marked clinical and radiological improvement after anti-tuberculosis therapy. Within 20 days of this apparent favorable evolution, the patient developed hemoptysis associated with rapid clinical deterioration. Imaging revealed a right hilar mass with metastatic disease. Bronchoscopic findings and histopathological examination confirmed lung adenocarcinoma (TTF-1 positive). This case highlights how apparent treatment response can be misleading and may delay the recognition of an underlying malignancy. Reassessment should be considered when the clinical course becomes atypical or rapidly progressive, particularly in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.